Advertisement

AstraZeneca to contest US court ruling over asthma medicine

Drugmaker AstraZeneca announced Tuesday that a US court ruled that its patent protecting its medicine Pulmicort Respules in the nation is invalid.

Drugmaker AstraZeneca announced Tuesday that a US court ruled that its patent protecting its medicine Pulmicort Respules in the nation is invalid.

The company said it strongly disagreed with the District Court of New Jersey's decision over the drug, which is used for the treatment of asthma.

"AstraZeneca has full confidence in the strength of its intellectual property rights protecting Pulmicort Respules," said Executive Vice President Paul Hudson.

Advertisement - Article continues below

"AstraZeneca is considering next steps, including an appeal of the court's decision."

The decision comes after AstraZeneca filed infringement lawsuits against Apotex, Watson Laboratories, Breath Limited and Sandoz for infringement of US patents directed to methods of use, formulation and form of active ingredient budesonide for Pulmicort Respules.

At the trial, the company said that the defendants' generic budesonide inhalation suspension products would infringe the claims of the two AstraZeneca patents.

The defendants denied the claims and asserted that each patent was invalid.

The firm stressed that the court's decision was limited to the US and has no impact on the validity of patents elsewhere.

It will also have no effect on the group's revenue guidance for 2013 which is for a mid to high-single digit decline in revenue on a constant currency basis, AstraZeneca insisted.

However, if additional generics enter the market it would materially impact royalties received on sales of Pulmicort Respules.

Royalties represented an annualised value of approximately $260m in 2012 under the core other income line in the company's annual report.

Subject to additional generics entering the market, guidance for core other income in 2013 is estimated to be significantly below $600m. The company expects core earnings per share to fall more than revenue in 2013.

RD

Advertisement
Advertisement

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

An economics lesson from my barber
Inflation

An economics lesson from my barber

On reopening his shop after lockdown, Dominic Frisby’s barber doubled his prices. It’s all part of the post-Covid inflation process – and we’re going …
8 Jul 2020
Can Rishi Sunak save the economy with stamp duty cuts and half-price meal deals?
UK Economy

Can Rishi Sunak save the economy with stamp duty cuts and half-price meal deals?

John Stepek runs his eye over the chancellor's £30bn stimulus package and asks if it's enough to get the economy back on its feet after months of lock…
9 Jul 2020
Have small companies lost their edge?
Sponsored

Have small companies lost their edge?

SPONSORED CONTENT – The tectonic plates beneath the modern investing landscape appear to have started moving in new directions
26 Jun 2020